ArticleBiochemistry and biophysics reports2025
Selective real-time disulfide reduction with simultaneous fluorescent labeling of a humanized anti-cocaine mAb.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A procedure for rapid screening and development of facile and limited partial reduction, with simultaneous fluorescent labeling, of a humanized anti-cocaine mAb was devised and characterized. This employed a standard soluble protein reductant, tris (2-carboxyethyl) phosphine (TCEP), paired with an alkylating agent that can be used without removal of the reductant, yielding a fluorescent adduct of the generated cysteine. This reaction can also be monitored by absorbance in a nanophotometer, allowing for rapid, simple screening of reduction and alkylation conditions using small mAb amounts and volumes. The degree of reduction is readily controllable, and yields results similar to limited reductions followed by separate labeling reactions, as recently reported using immobilized TCEP, and a less reactive phosphine reductant, triphenylphosphine-3,3',3″-trisulfonic acid (TPPTS). The overall structure of the mAb is not perturbed, and the thermal stability of the Fab portion of the mAb, where most selective disulfide reductions occur, is only minimally decreased. The antigen (cocaine) binding and binding thermodynamics are not changed, as demonstrated by isothermal titration calorimetry. However, differential scanning fluorimetry demonstrated that the thermal stabilization of the Fab domain by cocaine binding is dramatically decreased after reductive labeling to a level of 5.44 modified cys/mAb, suggesting the importance of light-heavy chain disulfide bonds for the cocaine-induced thermal stabilization of the mAb Fab. Methods described in this work should aid in the selective reduction and labeling of disulfides in mAbs and other proteins, assisting the assignment of structural and functional importance to specific protein disulfide bonds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.